2021-09-30| Special

What Does It Take for a Cell & Gene Therapy Program to Go Commercial?

by Sahana Shankar
Share To
In the past decade, cell and gene therapies have debuted successfully for various therapeutic areas and are no longer restricted to academic research trials. Therefore, building a cell and gene therapy company would require strategic and organizational capabilities that are slightly different from the conventional pharmaceutical landscape.

At the Reuters Events Cell & Gene Therapy Conference, several eminent speakers shared their views on what companies must consider while commercializing cell and gene therapies.

The session titled ‘Build and standardize an agile commercialization network’ was moderated by GeneOnline’s senior editor, Rajaneesh K. Gopinath. The panel consisted of the following experts.

Christine Strobele, Senior Director, US Launch lead- darvadstrocel at Takeda Sandra Anderson, Senior VP, Commercialization, and Strategy, Innomar Strategies Rita Johnson-Greene, VP Sales and Qualified Treatment Centers, bluebird bio Bethany Rogers,  VP Marketing- tabelecleucel, Atara Biotherapeutics

It's free! Log in now to read

OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
First-Ever Insect Brain Neuron Map Completed
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
Scroll to Top